Trial Profile

An Exploratory Clinical Study to Evaluate FX-322 in Patients Undergoing Cochlear Implant Surgery

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FX 322 (Primary)
Indications Sensorineural hearing loss
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

19 May 2020 New trial record
14 May 2020 According to a Frequency Therapeutics media release, Prof. Thomas Lenarz, Director of the Ear, Nose and Throat Clinic and the German Hearing Center of the Hannover Medical School is the principal investigator of this study.
14 May 2020 According to a Frequency Therapeutics media release, Frequency intends to present the results from this study at an upcoming medical conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com